Researchers from Apeximmune Therapeutics Inc. presented the discovery and preclinical evaluation of AIM-104, a novel potent pan-allele anti-SIRPĪ± antibody for the treatment of cancer.
Work at Laekna Therapeutics Shanghai Co. Ltd. has led to the discovery of a potent leukocyte immunoglobulin-like receptor subfamily B member 1/2 (LILRB1/LILRB2) antagonistic bispecific antibody, LAE-111, with improved antitumor activity.